{
    "relation": [
        [
            "",
            "DRV/Rtv 800/100 mg Once Daily",
            "DRV/Rtv 600/100 mg Twice Daily"
        ],
        [
            "Description",
            "Two 400 mg tablets of darunavir (DRV) + one 100 mg capsule of ritonavir (rtv) once daily",
            "One 600 mg darunavir (DRV) tablet + one 100 mg capsule of ritonavir (rtv) given twice daily"
        ]
    ],
    "pageTitle": "A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00524368?sect=X01256&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989790.89/warc/CC-MAIN-20150728002309-00027-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 869815931,
    "recordOffset": 869793904,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups In total 1092 participants were screened, of which 590 participants were randomly assigned and treated (294 participants were treated with DRV/rtv 800/100 mg once daily, and 296 participants with DRV/rtv 600/100 mg twice daily. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details One hundred thirteen investigators in 21 countries participated in this study. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Darunavir (DRV) Drug: Ritonavir (rtv) Interventions: Human Immunodeficiency Virus - Type 1 Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 DRV/Rtv 800/100 mg Once Daily \u00a0 \u00a0 DRV/Rtv 600/100 mg Twice Daily \u00a0 STARTED \u00a0 \u00a0 294 \u00a0 \u00a0 296 \u00a0 COMPLETED \u00a0 \u00a0 253 \u00a0 \u00a0 248 \u00a0 NOT COMPLETED \u00a0 \u00a0 41 \u00a0 \u00a0 48 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 10 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 12 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 9 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 13 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}